Focused On-demand Library for Galactoside-binding soluble lectin 13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9UHV8

UPID:

PP13_HUMAN

Alternative names:

Galectin-13; Placental tissue protein 13

Alternative UPACC:

Q9UHV8; C5HZ15

Background:

Galactoside-binding soluble lectin 13, also known as Galectin-13 or Placental tissue protein 13, is a protein that plays a crucial role in cellular processes. It binds to beta-galactoside and lactose, demonstrating significant involvement in T-cell apoptosis and hemagglutinating activity towards chicken erythrocytes. This protein's unique functions highlight its importance in the regulation of immune responses and cellular communication.

Therapeutic significance:

Understanding the role of Galactoside-binding soluble lectin 13 could open doors to potential therapeutic strategies. Its ability to induce T-cell apoptosis and its hemagglutinating activity suggest potential applications in immunotherapy and the treatment of diseases where immune regulation is compromised.